Tech Center 1600 • Art Units: 1641 1644
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18030901 | THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASE | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17284291 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18249991 | NATURAL KILLER CELLS WITH ENHANCED ACTIVITY | Non-Final OA | The Regents of the University of California |
| 18048386 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | Final Rejection | The Regents of the University of California |
| 18252442 | NOVEL LINKERS OF MULTISPECIFIC ANTIGEN BINDING DOMAINS | Non-Final OA | AMGEN INC. |
| 17436696 | GROWTH DIFFERENTIATION FACTOR 15 COMBINATION THERAPY | Final Rejection | Amgen Inc. |
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | Final Rejection | Novo Nordisk A/S |
| 18060215 | COMPOSITIONS AND METHODS FOR PURIFYING ALPHA-1 ANTITRYPSIN USING PEPTIDE LIGANDS | Non-Final OA | North Carolina State University |
| 19230637 | ANTICOAGULANT PROTEINS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH THE ACTIVATION OF NEUTROPHILS | Non-Final OA | BIOXODES |
| 18470044 | RAPID ELICITATION OF BROADLY NEUTRALIZING BOVINE ANTIBODIES TO HIV ENV | Final Rejection | The Texas A&M University System |
| 17868422 | SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION | Final Rejection | The Regents of the University of Michigan |
| 19086720 | Antigen Binding Proteins | Non-Final OA | ViiV Healthcare UK (No.5) Limited |
| 18034999 | CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | National University Corporation Tokai National Higher Education and Research System |
| 17292319 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING THE DEVELOPMENT OF FOOD ALLERGIES | Final Rejection | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18250106 | COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS | Non-Final OA | Intervet Inc. |
| 18018936 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17784025 | METHODS OF TREATING PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME USING AN ANTI-C5 ANTIBODY | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18030368 | NOVEL ANTI-GLYCAN ANTIBODY AND USE THEREOF | Non-Final OA | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY |
| 18452155 | METHODS FOR PREVENTING OR TREATING ALLERGY BY ADMINISTERING AN IL-4R ANTAGONIST | Final Rejection | SANOFI BIOTECHNOLOGY |
| 17996861 | LUCIFERASE LINKED IMMUNOSORBENT ASSAY | Non-Final OA | INSTITUT PASTEUR |
| 18305109 | Tau Immunotherapy | Non-Final OA | Prothena Biosciences Limited |
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | Non-Final OA | Aprilbio Co., Ltd. |
| 18183465 | Combinations of Modalities for the Treatment of Diabetes | Non-Final OA | Phaim Pharma Ltd. |
| 18148888 | COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION | Non-Final OA | Westfälische Wilhelms-Universität Münster |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy